TACT908
≈ 4 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
TACT908, also known as [2-(indolizin-1-yl)ethyl]dimethylamine (2ZEDMA), is a serotonin receptor agonist of the indolizinylethylamine family which is under development for the treatment of cluster headaches. It is a positional isomer of the tryptamine serotonergic psychedelic N,N-dimethyltryptamine (DMT) in which the indole ring has been replaced with an indolizine ring. The drug acts as a serotonin 5-HT 1B and 5-HT 2A receptor agonist. Its at the serotonin 5-HT 2A receptor is 52 nM ( ≈ 30% of that of serotonin) and its at the serotonin 5-HT 1B receptor is 143 nM. TACT908 is said to be a non-hallucinogenic serotonin 5-HT 2A receptor agonist. It showed little or no activity at 45 other screened targets, including the serotonin 5-HT 1A , 5-HT 2B , and 5-HT 3 receptors as well as the monoamine transporters (MATs). Other serotonin receptors besides the preceding, such as the serotonin 5-HT 2C receptor, were not assessed. The drug was a weak monoamine oxidase inhibitor (MAOI), specifically of monoamine oxidase A (MAO-A) ( = 7,252 nM). TACT908 is under development by Tactogen. It was patented by Matthew Baggott of Tactogen in 2023. As of January 2025, the drug is in preclinical research for cluster headaches.…
TACT908, also known as [2-(indolizin-1-yl)ethyl]dimethylamine (2ZEDMA), is a serotonin receptor agonist of the indolizinylethylamine family which is under development for the treatment of cluster headaches. It is a positional isomer of the tryptamine serotonergic psychedelic N,N-dimethyltryptamine (DMT) in which the indole ring has been replaced with an indolizine ring. The drug acts as a serotonin 5-HT 1B and 5-HT 2A receptor agonist. Its at the serotonin 5-HT 2A receptor is 52 nM ( ≈ 30% of that of serotonin) and its at the serotonin 5-HT 1B receptor is 143 nM. TACT908 is said to be a non-hallucinogenic serotonin 5-HT 2A receptor agonist. It showed little or no activity at 45 other screened targets, including the serotonin 5-HT 1A , 5-HT 2B , and 5-HT 3 receptors as well as the monoamine transporters (MATs). Other serotonin receptors besides the preceding, such as the serotonin 5-HT 2C receptor, were not assessed. The drug was a weak monoamine oxidase inhibitor (MAOI), specifically of monoamine oxidase A (MAO-A) ( = 7,252 nM). TACT908 is under development by Tactogen. It was patented by Matthew Baggott of Tactogen in 2023. As of January 2025, the drug is in preclinical research for cluster headaches. The α-methyl and N-desmethyl analogue of TACT908, 1ZP2MA ([1-(indolizin-1-yl)propan-2-yl](methyl)amine or 1-(indolizin-1-yl)-N-methylpropan-2-amine), has also been characterized and described. It is the indolizine analogue of α,N-dimethyltryptamine (α,N-DMT or N-methyl- ). 1ZP2MA was found to be a potent dopamine releasing agent, with an of 62 nM.
See also
Indolizinylethylamine Substituted tryptamine § Related compounds List of investigational hallucinogens and entactogens Non-hallucinogenic 5-HT 2A receptor agonist N,N-Dimethylisotryptamine (isoDMT) 1Z2MAP1O C-DMT S-DMT TACT411 Rizatriptan TACT833
References
External links
TACT908 (2ZEDMA) - Isomer Design
Text derived from https://en.wikipedia.org/w/index.php?oldid=1332268291 under CC BY-SA 4.0; modifications have been made.